• Abd El-Atti S, Wasicek K, Mark S, Hegazi R. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN J. Parenter. Enteral Nutr. 33: 569-570 (2009). *

• Abdelrazeq AS, Kandiyil N, Botterill ID, Lund JN, Reynolds JR, Holdsworth PJ, Leveson SH. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 10: 805-813 (2008). *

• Abdelrazeq AS, Lund JN, Leveson SH. Implications of pouchitis on the functional results following stapled restorative proctocolectomy. Dis. Colon Rectum 48: 1700-1707 (2005). *

• Abdelrazeq AS, Lund JN, Leveson SH. Pouchitis-associated pyoderma gangrenosum following restorative proctocolectomy for ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 16: 1057-1058 (2004).

• Abdelrazeq AS, Wilson TR, Leitch DL, Lund JN, Leveson SH. Ileitis in ulcerative colitis: is it a backwash? Dis. Colon Rectum 48: 2038-2046 (2005). *

• Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol. Rep. 4: 481-489 (2002).

• Achkar JP, Al-Haddad M, Lashner B, Remzi FH, Brzezinski A, Shen B, Khandwala F, Fazio V. Differentiating risk factors for acute and chronic pouchitis. Clin. Gastroenterol. Hepatol. 3: 60-66 (2005). *

• Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, et al. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am. J. Gastroenterol. 101: 572-580 (2006). *

• Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, Hegazi RAF, Yager J, Bodian C, Gorfine SR, Bauer JJ, Plevy SE, Sachar DB. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am. J. Gastroenterol. 99: 432-441 (2004). *

• Aisenberg J, Wagreich J, Shim J, Almer S, Peen E, Heimann T, Gelernt IM, Greenstein A, Rubin P, Harpaz N, et al. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Dig. Dis. Sci. 40: 1866-1872 (1995).

• Aitola P, Matikainen M, Mattila J, Tomminen T, Hiltunen KM. Chronic inflammatory changes in the pouch mucosa are associated with cholangitis found on peroperative liver biopsy specimens at restorative proctocolectomy for ulcerative colitis. Scand. J. Gastroenterol. 33: 289-293 (1998). *

• Akerlund JE, Lofberg R. Pouchitis. Curr. Opin. Gastroenterol. 20: 341-344 (2004).

• Alexander F. Complications of ileal pouch anal anastomosis. Semin. Pediatr. Surg. 16: 200-204 (2007).

• Almeghaiseeb ES. Probiotics: an overview and their role in inflammatory bowel disease. Saudi J. Gastroenterol. 13: 150-152 (2007). *

• Amasheh S, Dullat S, Fromm M, Schulzke JD, Buhr HJ, Kroesen AJ. Inflamed pouch mucosa possesses altered tight junctions indicating recurrence of inflammatory bowel disease. Int. J. Colorectal Dis. 24: 1149-1156 (2009). *

• Amati L, Pepe M, Passeri ME, Mastronardi ML, Jirillo E, Covelli V. Toll-like receptor signaling mechanisms involved in dendritic cell activation: potential therapeutic control of T cell polarization. Curr. Pharm. Des. 12: 4247-4254 (2006).

• Araki Y, Mitsuyama K, Nagae T, Tou Y, Nakagawa M, Iwatani Y, Harada M, Ozasa H, Sata M, Noake T. Leukocytapheresis for the treatment of active pouchitis: a pilot study. J. Gastroenterol. 43: 571-575 (2008). *

• Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment. Pharmacol. Ther. 15: 1639-1646 (2001). *

• Baczuk L, Krzysztof B. Pouchitis - what do we know after 30 years? Wiad. Lek. 61: 201-206 (2008).

• Baert FJ, Rutgeerts PJ. Medical therapies for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 2: 446-450 (2000).

• Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev. Gastroenterol. Disord. 5: 19-30 (2005).

• Balbir-Gurman A, Schapira D, Nahir M. Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis. Semin. Arthritis Rheum. 30: 242-248 (2001). *

• Ball CG, Maclean AR, Buie WD, Smith DF, Raber EL. Portal vein thrombi after ileal pouch-anal anastomosis: its incidence and association with pouchitis. Surg. Today 37: 552-557 (2007).

• Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 100: 2560-2568 (2005). *

• Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. 101: 1048-1056 (2006). *

• Becker JM, Stucchi AF, Bryant DE. How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis. 4: 167-169 (1998). *

• Belkahla N, Maamouri N, Ouerghi H, Ben Ammar A. Role of intestinal flora in inflammatory bowel disease and probiotics place in their management. Tunis. Med. 83: 132-136 (2005).

• Bell AJ, Nicholls RJ, Forbes A, Ellis HJ, Ciclitira PJ. Human lymphocyte stimulation with pouchitis flora is greater than with flora from a healthy pouch but is suppressed by metronidazole. Gut 53: 1801-1805 (2004). *

• Bell AJ, Price AB, Forbes A, Ciclitira PJ, Groves C, Nicholls RJ. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis. 8: 402-410 (2006). *

• Belluzzi A, Serrani M, Roda G, Bianchi ML, Castellani L, Grazia M, Rosati G, Ugolini G, Roda E. Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. Aliment. Pharmacol. Ther. 31: 228-232 (2010). *

• Bengtsson J, Borjesson L, Lundstam U, Oresland T. Long-term function and manovolumetric characteristics after ileal pouch-anal anastomosis for ulcerative colitis. Br. J. Surg. 94: 327-332 (2007). *

• Biancone L, Palmieri G, Lombardi A, Colantoni A, Tonelli F, Das KM, Pallone F. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis. Am. J. Gastroenterol. 98: 2719-2726 (2003). *

• Biancone L, Palmieri G, Lombardi A, Vavassori P, Monteleone I, Del Vecchio Blanco G, Colantoni A, Spagnoli L, Tonelli F, Pallone F. Cytoskeletal proteins and resident flora. Dig. Liver Dis. 34 Suppl. 2: S34-S36 (2002).

• Biancone L, Schillaci O, Capoccetti F, Bozzi RM, Fina D, Petruzziello C, Geremia A, Simonetti G, Pallone F. Technetium-99m-HMPAO labeled leukocyte single photon emission computerized tomography (SPECT) for assessing Crohn's disease extent and intestinal infiltration. Am. J. Gastroenterol. 100: 344-354 (2005). *

• Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523 (2003).

• Bohm S, Kruis W. Probiotics in chronic inflammatory bowel disease. MMW Fortschr. Med. 148: 30-34 (2006).

• Bohm SK, Kruis W. Probiotics: do they help to control intestinal inflammation? Ann. N. Y. Acad. Sci. 1072: 339-350 (2006). *

• Borjesson L, Willen R, Haboubi N, Duff SE, Hulten L. The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: a long-term term follow-up study. Colorectal Dis. 6: 494-498 (2004). *

• Bosso MC, Marchesa PE, Ricchiuti A, Giacardi A, Cocchis D, Campi M, Palisi M, Salizzoni M. Proctocolectomy for ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Transplant. Proc. 41: 1390-1392 (2009). *

• Braveman JM, Schoetz DJ Jr, Marcello PW, Roberts PL, Coller JA, Murray JJ, Rusin LC. The fate of the ileal pouch in patients developing Crohn's disease. Dis. Colon Rectum 47: 1613-1619 (2004).

• Brazowski E, Dotan I, Tulchinsky H, Filip I, Eisenthal A. Galectin-3 expression in pouchitis in patients with ulcerative colitis who underwent ileal pouch-anal anastomosis (IPAA). Pathol. Res. Pract. 205: 551-558 (2009).

• Brett PM, Yasuda N, Yiannakou JY, Herbst F, Ellis HJ, Vaughan R, Nicholls RJ, Ciclitira PJ. Genetic and immunological markers in pouchitis. Eur. J. Gastroenterol. Hepatol. 8: 951-955 (1996).

• Broder JC, Tkacz JN, Anderson SW, Soto JA, Gupta A. Ileal pouch-anal anastomosis surgery: imaging and intervention for post-operative complications. Radiographics 30: 221-233 (2010).

• Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26: 31-41 (2006). *

• Bulois P, Tremaine WJ, Maunoury V, Gambiez L, Hafraoui S, Leteurtre L, Cortot A, Sandborn WJ, Colombel JF, Desreumaux P. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm. Bowel Dis. 6: 157-164 (2000). *

• Bulow S, Walker LR. Restorative proctocolectomy with an ileoanal pouch - course, complications and long-term functional results. Ugeskr. Laeger. 170: 1721-1725 (2008).

• Bunni J, Monkhouse SJ, Probert CJ, Norton SA, Durdey P, Morgan JD. Complete resolution of intractable pouchitis in an obese patient following laparoscopic gastric banding. Colorectal Dis. Sep 14 [Epub ahead of print] (2009). *

• Cabre E, Gassull MA. Probiotics for preventing relapse or recurrence in Crohn’s disease involving the ileum: are there reasons for failure? Journal of Crohn's and Colitis 1: 47-52 (2007).

• Cabre E, Gassull MA. Nutritional and metabolic issues in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 6: 569-576 (2003).

• Cabriada Nuno JL, Hernandez Martin A, Bernal Martinez A, Zabalza Estevez I. Oral budesonide in the treatment of chronic refractory pouchitis. Gastroenterol. Hepatol. 31: 485-489 (2008).

• Calabrese C, Fabbri A, Gionchetti P, Rizzello F, Morselli C, Liguori G, Poggioli G, Campieri M, Febo GD. Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment. Pharmacol. Ther. 25: 1311-1316 (2007).

• Calabrese C, Gionchetti P, Rizzello F, Liguori G, Gabusi V, Tambasco R, Poggioli G, Pierangeli F, Campieri M, Di Febo G. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment. Pharmacol. Ther. 27: 759-764 (2008). *

• Carter MJ, Di Giovine FS, Cox A, Goodfellow P, Jones S, Shorthouse AJ, Duff GW, Lobo AJ. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 121: 805-811 (2001). *

• Casadesus D, Tani T, Wakai T, Maruyama S, Iiai T, Okamoto H, Hatakeyama K. Possible role of human cytomegalovirus in pouchitis after proctocolectomy with ileal pouch-anal anastomosis in patients with ulcerative colitis. World J. Gastroenterol. 13: 1085-1089 (2007). *

• Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).

• Chapman TM, Plosker GL, Figgitt DP. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. BioDrugs 21: 61-63 (2007).

• Chapman TM, Plosker GL, Figgitt DP. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs 66: 1371-1387 (2006).

• Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J. Clin. Gastroenterol. 38: S44-S50 (2004).

• Chermesh I, Eliakim R. Probiotics and the gastrointestinal tract: where are we in 2005? World J. Gastroenterol. 12: 853-857 (2006). *

• Cho CS, Dayton MT, Thompson JS, Koltun WA, Heise CP, Harms BA. Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis after liver transplantation for primary sclerosing cholangitis: a multi-institutional analysis. J. Gastrointest. Surg. 12: 1221-1226 (2008). *

• Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm. Bowel Dis. 12: 29-32 (2006). *

• Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 71-75 (2009).

• Coffey JC, Rowan F, Burke J, Dochery N, Kirwan WO, O'Connell PR. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am. J. Gastroenterol. 104: 1013-1023 (2009). *

• Coffey JC, Winter DC, Neary P, Murphy A, Redmond HP, Kirwan WO. Quality of life after ileal pouch-anal anastomosis: an evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. Dis. Colon Rectum 45: 30-38 (2002).

• Cohen RD. Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505 (2002).

• Colombel JF. IBD: genotypes - phenotypes. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 19 (2005). *

• Coran AG. Management of pouchitis. Inflamm. Bowel Dis. 4: 333 (1998). *

• Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opin. Biol. Ther. 6: 401-408 (2006).

• Cottone M, Orlando A, Modesto I. Postoperative maintenance therapy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 22: 377-381 (2006).

• Crema MD, Richarme D, Azizi L, Hoeffel CC, Tubiana JM, Arrive L. Pouchography, CT, and MRI features of ileal J pouch-anal anastomosis. AJR Am. J. Roentgenol. 187: W594-W603 (2006). *

• Cruz-Correa M, Giardiello FM, Bayless TM. Atypical forms of inflammatory bowel disease: microscopic colitis and pouchitis. Curr. Opin. Gastroenterol. 16: 343-348 (2000).

• Cummings JH, Kong SC. Probiotics, prebiotics and antibiotics in inflammatory bowel disease. Novartis Found. Symp. 263: 99-111 (2004).

• Cummings JH, Macfarlane GT, Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr. Issues Intest. Microbiol. 4: 9-20 (2003).

• Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, Pera A. Outcome of a conservative approach in severe ulcerative colitis. Dig. Liver Dis. 36: 21-28 (2004). *

• Das P, Johnson MW, Tekkis PP, Nicholls RJ. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 9: 15-27 (2007). *

• De Hertogh G, Geboes K. Crohn's disease and infections: a complex relationship. MedGenMed. 6: 14 (2004). *

• De La Rue SA, Bickston SJ. Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22: 365-369 (2006).

• de Oca J, Vilar L, Castellote J, Sanchez Santos R, Pares D, Biondo S, Osorio A, del Rio C, Jaurrieta E, Marti Rague J. Immunodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev. Esp. Enferm. Dig. 95: 465-470, 459-464 (2003).

• De Preter V, Bulteel V, Suenaert P, Geboes KP, De Hertogh G, Luypaerts A, Geboes K, Verbeke K, Rutgeerts P. Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa. Inflamm. Bowel Dis. 15: 335-340 (2009).

• de Silva HJ, Gatter KC, Millard PR, Kettlewell M, Mortensen NJ, Jewell DP. Crypt cell proliferation and HLA-DR expression in pelvic ileal pouches. J. Clin. Pathol. 43: 824-828 (1990). *

• Deibert P, Konig D, Becker G, Berg A. Usefulness of probiotics in prevention and therapy. Dtsch. Med. Wochenschr. 135: 345-349 (2010).

• Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, Lamorte W, Farraye FA. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. J. Gastrointest. Surg. 10: 1060-1064 (2006).

• Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, Grenther WB, Sartor RB. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52: 370-376 (2003). *

• Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr. Opin. Gastroenterol. 21: 426-430 (2005).

• Duffy M, O'Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP, Kirwan WO. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis. Colon Rectum 45: 384-388 (2002).

• El-Raouf AA, Hak NG, Fathy O, El-Ebidy G, Salah T, El-Hemaly M. Outcome of pouch surgery for ulcerative colitis: single center experience. Hepatogastroenterology 55: 2130-2134 (2008).

• Esteve M, Mallolas J, Klaassen J, Abad-Lacruz A, Gonzalez-Huix F, Cabre E, Fernandez-Banares F, Menacho M, Condom E, Marti-Rague J, Gassull MA. Factors related to the presence of IgA class antineutrophil cytoplasmic antibodies in ulcerative colitis. Am. J. Gastroenterol. 93: 615-618 (1998). *

• Ettorre GM, Pescatori M, Panis Y, Nemeth J, Crescenzi A, Valleur P. Mucosal changes in ileal pouches after restorative proctocolectomy for ulcerative and Crohn's colitis. Dis. Colon Rectum 43: 1743-1748 (2000).

• Evgenikos N, Bartolo DC, Hamer-Hodges DW, Ghosh S. Assessment of ileoanal pouch inflammation by interleukin 1beta and interleukin 8 concentrations in the gut lumen. Dis. Colon Rectum 45: 249-255 (2002).

• Evgenikos NL, Bartolo DC, Hamer-Hodges DW, Ghosh S. Luminal neutrophil migration in ileoanal pouches studied by whole gut lavage. Eur. J. Gastroenterol. Hepatol. 12: 553-557 (2000).

• Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J. Gastroenterol. 12: 5941-5950 (2006). *

• Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr. Gastroenterol. Rep. 8: 486-498 (2006).

• Falk A, Olsson C, Ahrne S, Molin G, Adawi D, Jeppsson B. Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens. Scand. J. Gastroenterol. 42: 973-985 (2007). *

• Famularo G, De Simone C, Matteuzzi D, Pirovano F. Traditional and high potency probiotic preparations for oral bacteriotherapy. BioDrugs 12: 455-470 (1999).

• Faubion WA Jr, Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J. Pediatr. Gastroenterol. Nutr. 33: 296-300 (2001). *

• Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr. Opin. Gastroenterol. 20: 146-155 (2004).

• Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis. 10: 286-299 (2004). *

• Fefferman DS, Farrell RJ. Making sense of antisense: ISIS 2302 (Alicaforsen) in the treatment of pouchitis. Inflamm. Bowel Dis. 10: 487-488 (2004). *

• Ferrante M, D'Haens G, Dewit O, Baert F, Holvoet J, Geboes K, De Hertogh G, Van Assche G, Vermeire S, Rutgeerts P; on behalf of the Belgian IBD Research Group. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm. Bowel Dis. 16: 243-249 (2010).

• Ferrante M, Declerck S, Coopmans T, De Hertogh G, Van Assche G, Penninckx F, Rutgeerts P, Geboes K, D'Hoore A, Vermeire S. Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: a role for serological markers and microbial pattern recognition receptor genes? Journal of Crohn's and Colitis 2: 142-151 (2008).

• Ferrante M, Declerck S, De Hertogh G, Van Assche G, Geboes K, Rutgeerts P, Penninckx F, Vermeire S, D'Hoore A. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm. Bowel Dis. 14: 20-28 (2008). *

• Finnie IA, Taylor BA, Rhodes JM. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. Gut 34: 1552-1528 (1993). *

• Fleshner P, Ippoliti A, Dubinsky M, Vasiliauskas E, Mei L, Papadakis KA, Rotter JI, Landers C, Targan S. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin. Gastroenterol. Hepatol. 6: 561-568 (2008). *

• Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaiennie J, Abreu-Martin MT, Targan SR. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 49: 671-677 (2001). *

• Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 283-288 (2003).

• Floch MH, Madsen KK, Jenkins DJ, Guandalini S, Katz JA, Onderdonk A, Walker WA, Fedorak RN, Camilleri M. Recommendations for probiotic use. J. Clin. Gastroenterol. 40: 275-278 (2006).

• Floch MH, Walker WA, Guandalini S, Hibberd P, Gorbach S, Surawicz C, Sanders ME, Garcia-Tsao G, Quigley EM, Isolauri E, Fedorak RN, Dieleman LA. Recommendations for probiotic use - 2008. J. Clin. Gastroenterol. 42 Suppl. 2: S104-S108 (2008).

• Fogt F, Deren JJ, Nusbaum M, Wellmann A, Ross HM. Pouchitis in ulcerative colitis: correlation between predictors from colectomy specimens and clinico-histological features. Eur. Surg. Res. 38: 407-413 (2006).

• Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br. J. Nutr. 88 Suppl. 1: S39-S49 (2002). *

• Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr. Opin. Gastroenterol. 24: 4-10 (2008). *

• Freeman HJ. Recent developments on the role of Clostridium difficile in inflammatory bowel disease. World J. Gastroenterol. 14: 2794-2796 (2008). *

• Freeman HJ. Inflammatory bowel diseases in Indo-Canadians with and without antineutrophil cytoplasmic autoantibodies. Can. J. Gastroenterol. 14: 21-26 (2000). *

• Freeman HJ, Roeck B, Devine DV, Carter CJ. Atypical perinuclear antineutrophil cytoplasmic antibodies after colectomy in inflammatory bowel disease. Can. J. Gastroenterol. 11: 305-310 (1997). *

• Freeman K, Shao Z, Remzi FH, Lopez R, Fazio VW, Shen B. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin. Gastroenterol. Hepatol. 6: 62-68 (2008).

• Fukushima K, Fujii H, Yamamura T, Sugita A, Kameoka S, Nagawa H, Futami K, Watanabe T, Hatakeyama K, Sawada T, Yoshioka K, Kusunoki M, Konishi F, Watanabe M, Takahashi K, Ogawa H, Funayama Y, Hibi T, Sasaki I. Pouchitis atlas for objective endoscopic diagnosis. J. Gastroenterol. 42: 799-806 (2007). *

• Garrett KA, Remzi FH, Kirat HT, Fazio VW, Shen B, Kiran RP. Outcome of salvage surgery for ileal pouches referred with a diagnosis of Crohn's disease. Dis. Colon Rectum 52: 1967-1974 (2009).

• Gassull MA. Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease. Aliment. Pharmacol. Ther. 24 Suppl. 3: 90-95 (2006). *

• Gerard L, Garey KW, Dupont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev. Anti. Infect. Ther. 3: 201-211 (2005).

• Gertner DJ, Rampton DS, Madden MV, Talbot IC, Nicholls RJ, Lennard-Jones JE. Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis. Gut 35: 1429-1432 (1994). *

• Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv. Exp. Med. Biol. 606: 423-454 (2008).

• Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80: 516-526 (2004). *

• Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment. Pharmacol. Ther. 16 Suppl. 4: 13-19 (2002). *

• Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, Campieri M. Diagnosis and treatment of pouchitis. Best Pract. Res. Clin. Gastroenterol. 17: 75-87 (2003).

• Gionchetti P, Morselli C, Rizzello F, Romagnoli R, Campieri M, Poggioli G, Laureti S, Ugolini F, Pierangeli F. Management of pouch dysfunction or pouchitis with an ileoanal pouch. Best Pract. Res. Clin. Gastroenterol. 18: 993-1006 (2004).

• Gionchetti P, Rizzello F, Campieri M. Probiotics and antibiotics in inflammatory bowel disease. Curr. Opin. Gastroenterol. 17: 331-335 (2001).

• Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209 (2003). *

• Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J. Gastroenterol. 12: 3306-3313 (2006). *

• Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M. Antimicrobials in the management of inflammatory bowel disease. Digestion 73 Suppl. 1: 77-85 (2006). *

• Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini G, Campieri M. High-dose probiotics for the treatment of active pouchitis. Dis. Colon Rectum 50: 2075-2082 (2007). *

• Gionchetti P, Rizzello F, Morselli C, Romagnoli R, Campieri M. Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 51 Suppl. 1: 96-102 (2005).

• Gionchetti P, Rizzello F, Poggioli G, Pierangeli F, Laureti S, Morselli C, Tambasco R, Calabrese C, Campieri M. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment. Pharmacol. Ther. 25: 1231-1236 (2007). *

• Gionchetti P, Rizzello F, Tambasco R, Straforini G, Poggioli G, Calabrese C, Brugnera R, Campieri M. Which therapies are advisable in pouchitis? Inflamm. Bowel Dis. 14 Suppl. 2: S241-S242 (2008). *

• Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309 (2000). *

• Goldstein ES, Rubin PH. Endoscopic therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 237-243 (2003).

• Goldstein NS, Sanford WW, Bodzin JH. Crohn's-like complications in patients with ulcerative colitis after total proctocolectomy and ileal pouch-anal anastomosis. Am. J. Surg. Pathol. 21: 1343-1353 (1997).

• Goossens D, Jonkers D, Stobberingh E, van den Bogaard A, Russel M, Stockbrugger R. Probiotics in gastroenterology: indications and future perspectives. Scand. J. Gastroenterol. Suppl. 239: 15-23 (2003). *

• Gorgun E, Remzi FH, Manilich E, Preen M, Shen B, Fazio VW. Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery 138: 631-637 (2005). *

• Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis. Colon Rectum 47: 1519-1525 (2004). *

• Gosselink MP, Schouten WR, Van Lieshout LM, Hop WC, Laman JD, Ruseler-Van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis. Colon Rectum 47: 876-884 (2004). *

• Grucela AL, Bauer JJ, Gorfine SR, Chessin DB. Outcome and long-term function of restorative proctocolectomy for Crohn's disease: comparison to patients with ulcerative colitis. Colorectal Dis. Dec 14 [Epub ahead of print] (2009). *

• Grucela AL, Steinhagen RM. Restorative proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis after liver transplant for primary sclerosing cholangitis: case report and review of literature. Am. Surg. 71: 362-365 (2005).

• Guarner F. Inulin and oligofructose: impact on intestinal diseases and disorders. Br. J. Nutr. 93 Suppl. 1: S61-S65 (2005).

• Guarner F. Prebiotics in inflammatory bowel diseases. Br. J. Nutr. 98 Suppl. 1: S85-S89 (2007). *

• Guarner F. Prebiotics, probiotics and helminths: the 'natural' solution? Dig. Dis. 27: 412-417 (2009).

• Gupta A, Derbes C, Sellin J. Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an academic medical center. Inflamm. Bowel Dis. 11: 898-902 (2005). *

• Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur. J. Gastroenterol. Hepatol. 17: 145-147 (2005).

• Hahnloser D, Pemberton JH, Wolff BG, Larson D, Harrington J, Farouk R, Dozois RR. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. Dis. Colon Rectum 47: 1127-1135 (2004). *

• Hahnloser D, Pemberton JH, Wolff BG, Larson DR, Crownhart BS, Dozois RR. The effect of ageing on function and quality of life in ileal pouch patients: a single cohort experience of 409 patients with chronic ulcerative colitis. Ann. Surg. 240: 615-623 (2004). *

• Hait EJ, Bousvaros A, Schuman M, Shamberger RC, Lillehei CW. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J. Pediatr. Surg. 42: 31-34 (2007).

• Haller D, Antoine JM, Bengmark S, Enck P, Rijkers GT, Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J. Nutr. Jan 27 [Epub ahead of print] (2010).

• Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 126: 1582-1592 (2004). *

• Hanauer SB, Sparrow M. Therapy of ulcerative colitis. Curr. Opin. Gastroenterol. 20: 345-350 (2004).

• Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand. J. Gastroenterol. 38: 1055-1058 (2003). *

• Hauser W, Dietz N, Grandt D, Steder-Neukamm U, Janke KH, Stein U, Stallmach A. Validation of the inflammatory bowel disease questionnaire IBDQ-D, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis. Z. Gastroenterol. 42: 131-139 (2004).

• Hauser W, Dietz N, Steder-Neukamm U, Janke KH, Stallmach A. Biopsychosocial determinants of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Inflamm. Bowel Dis. 10: 399-407 (2004). *

• Heczko PB, Strus M, Kochan P. Critical evaluation of probiotic activity of lactic acid bacteria and their effects. J. Physiol. Pharmacol. 57 Suppl. 9: 5-12 (2007). *

• Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc. Nutr. Soc. 66: 307-315 (2007). *

• Heilpern D, Szilagyi A. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. Rev. Recent Clin. Trials 3: 167-184 (2008).

• Heller F, Duchmann R. Intestinal flora and mucosal immune responses. Int. J. Med. Microbiol. 293: 77-86 (2003).

• Helwig U, Gionchetti P, Rizzello F, Lammers K, Kuhbacher T, Schreiber S, Baggiolini M, Uguccioni M, Campieri M. CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. Int. J. Colorectal Dis. 19: 165-170 (2004). *

• Heriot AG, Tekkis PP, Smith JJ, Bona R, Cohen RG, Nicholls RJ. Management and outcome of pouch-vaginal fistulas following restorative proctocolectomy. Dis. Colon Rectum 48: 451-458 (2005). *

• Heuschen G, Leowardi C, Hinz U, Autschbach F, Stallmach A, Herfarth C, Heuschen UA. Differential expression of Toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients. Int. J. Colorectal Dis. 22: 293-301 (2007). *

• Hinojosa J, Bau I, Martinez B, Garcia Armengol J, Roig JV, Ferrando J, Moles JR, Gomez AB, Lledo S. Morphological, histochemical and immunochemical characteristics of the terminal ileum of patients with ulcerative colitis. Relationship with the development of pouchitis. Gastroenterol. Hepatol. 23: 263-268 (2000).

• Hirata N, Oshitani N, Kamata N, Sogawa M, Yamagami H, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y, Maeda K, Hirakawa K, Arakawa T. Proliferation of immature plasma cells in pouchitis mucosa in patients with ulcerative colitis. Inflamm. Bowel Dis. 14: 1084-1090 (2008). *

• Hoda KM, Collins JF, Knigge KL, Deveney KE. Predictors of pouchitis after ileal pouch-anal anastomosis: a retrospective review. Dis. Colon Rectum 51: 554-560 (2008). *

• Hori K, Ikeuchi H, Nakano H, Uchino M, Tomita T, Ohda Y, Hida N, Matsumoto T, Fukuda Y, Miwa H. Gastroduodenitis associated with ulcerative colitis. J. Gastroenterol. 43: 193-201 (2008). *

• Hui T, Landers C, Vasiliauskas E, Abreu M, Dubinsky M, Papadakis KA, Price J, Lin YC, Huiying Y, Targan S, Fleshner P. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis. Colon Rectum 48: 1254-1262 (2005). *

• Hurst RD, Chung TP, Rubin M, Michelassi F. The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm. Bowel Dis. 4: 280-284 (1998). *

• Iivonen MK, Mattila JJ, Nordback IH, Matikainen MJ. Long-term follow-up of patients with jejunal pouch reconstruction after total gastrectomy. A randomized prospective study. Scand. J. Gastroenterol. 35: 679-685 (2000). *

• Ikeuchi H, Hori K, Nishigami T, Nakano H, Uchino M, Nakamura M, Kaibe N, Noda M, Yanagi H, Yamamura T. Diffuse gastroduodenitis and pouchitis associated with ulcerative colitis. World J. Gastroenterol. 12: 5913-5915 (2006). *

• Ikeuchi H, Nakano H, Uchino M, Nakamura M, Yanagi H, Noda M, Yamamura T. Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients. Dig. Surg. 21: 197-201 (2004).

• Ingram S, McKinley JM, Vasey F, Carter JD, Brady PG. Are inflammatory bowel disease (IBD) and pouchitis a reactive enteropathy to group D streptococci (Enterococci)? Inflamm. Bowel Dis. 15: 1609-1610 (2009).

• Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ, Crohn's and Colitis Foundation of America Clinical Alliance. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis. 13: 1250-1255 (2007). *

• Iwata T, Yamamoto T, Umegae S, Matsumoto K. Pouchitis and pre-pouch ileitis developed after restorative proctocolectomy for ulcerative colitis: a case report. World J. Gastroenterol. 13: 643-646 (2007). *

• Iwaya A, Iiai T, Okamoto H, Ajioka Y, Yamamoto T, Asahara T, Nomoto K, Hatakeyama K. Change in the bacterial flora of pouchitis. Hepatogastroenterology 53: 55-59 (2006).

• Jimmo B, Hyman NH. Is ileal pouch-anal anastomosis really the procedure of choice for patients with ulcerative colitis? Dis. Colon Rectum 41: 41-45 (1998).

• Joelsson M, Benoni C, Oresland T. Does smoking influence the risk of pouchitis following ileal pouch anal anastomosis for ulcerative colitis? Scand. J. Gastroenterol. 41: 929-933 (2006). *

• Johnson MW, Das P, Dewar DH, Forbes A, Ciclitira PJ, Nicholls RJ. Medical management of patients with ileal pouch anal anastomosis after restorative procto-colectomy. Eur. J. Gastroenterol. Hepatol. 21: 9-17 (2009).

• Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Ciclitira PJ, Sherwood RA, Nicholls JR. Faecal M2-pyruvate kinase: a novel, noninvasive marker of ileal pouch inflammation. Eur. J. Gastroenterol. Hepatol. 21: 544-550 (2009).

• Johnson MW, Maestranzi S, Duffy AM, Dewar DH, Forbes A, Bjarnason I, Sherwood RA, Ciclitira P, Nicholls JR. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur. J. Gastroenterol. Hepatol. 20: 174-179 (2008).

• Johnson MW, Rogers GB, Bruce KD, Lilley AK, von Herbay A, Forbes A, Ciclitira PJ, Nicholls RJ. Bacterial community diversity in cultures derived from healthy and inflamed ileal pouches after restorative proctocolectomy. Inflamm. Bowel Dis. 15: 1803-1811 (2009). *

• Jonkers D, Stockbrugger R. Review article: probiotics in gastrointestinal and liver diseases. Aliment. Pharmacol. Ther. 26 Suppl. 2: 133-148 (2007). *

• Joo M, Abreu-E-Lima P, Farraye F, Smith T, Swaroop P, Gardner L, Lauwers GY, Odze RD. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am. J. Surg. Pathol. 33: 854-862 (2009).

• Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR. Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 26: 386-392 (1998). *

• Kamm MA. Manipulation of enteric flora in clinical practice. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 36. May 7-8 (2004). *

• Kanai T, Nemoto Y, Kamada N, Totsuka T, Hisamatsu T, Watanabe M, Hibi T. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Curr. Opin. Gastroenterol. 25: 306-313 (2009). *

• Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. Drugs Today (Barc.) 41: 453-459 (2005).

• Kartheuser A, Stangherlin P, Brandt D, Remue C, Sempoux C. Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited. Fam. Cancer 5: 241-260 (2006). *

• Kartheuser AH, Dozois RR, LaRusso NF, Wiesner RH, Ilstrup DM, Schleck CD. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin. Proc. 71: 748-756 (1996). *

• Keranen U, Jarvinen H, Kiviluoto T, Kivilaakso E, Soinila S. Substance P- and vasoactive intestinal polypeptide-immunoreactive innervation in normal and inflamed pouches after restorative proctocolectomy for ulcerative colitis. Dig. Dis. Sci. 41: 1658-1664 (1996).

• Keswani RN, Cohen RD. Postoperative management of ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 7: 492-499 (2005).

• Kiehne K, Brunke G, Wegner F, Banasiewicz T, Folsch UR, Herzig KH. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J. Gastroenterol. 12: 1056-1062 (2006). *

• Kirchgatterer A, Knoflach P. Natural therapy instead of chemistry? Probiotics in gastroenterology. Acta Med. Austriaca 31: 13-17 (2004).

• Klebl FH, Bregenzer N, Rogler G, Straub RH, Scholmerich J, Andus T. Treatment of pouchitis with dehydroepiandrosterone (DHEA) - a case report. Z. Gastroenterol. 41: 1087-1090 (2003).

• Klinge LG, Kjeldsen J. Probiotics: should we change the treatment strategy for pouchitis? Ugeskr. Laeger. 168: 3516-3518 (2006).

• Knupper N, Straub E, Terpe HJ, Vestweber KH. Adenocarcinoma of the ileoanal pouch for ulcerative colitis - a complication of severe chronic atrophic pouchitis? Int. J. Colorectal Dis. 21: 478-482 (2006). *

• Koh PK, Doumit J, Downs-Kelly E, Bronner MP, Salimi R, Fazio VW, Vogel JD. Ileo-anal J-pouch cancer: an unusual case in an unusual location. Tech. Coloproctol. 12: 341-345 (2008). *

• Kohyama M, Takesue Y, Ohge H, Murakami Y, Shimamoto F, Sueda T. Pouchitis disease activity index (PDAI) does not predict patients with symptoms of pouchitis who will respond to antibiotics. Surg. Today 39: 962-968 (2009).

• Koivusalo A, Pakarinen MP, Rintala RJ. Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. J. Pediatr. Surg. 42: 290-295 (2007).

• Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin. Gastroenterol. Hepatol. 5: 352-360 (2007).

• Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm. Bowel Dis. 12: 524-534 (2006). *

• Koo HL, Dupont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr. Opin. Gastroenterol. 26: 17-25 (2010).

• Kooros K, Katz AJ. Infliximab therapy in pediatric Crohn's pouchitis. Inflamm. Bowel Dis. 10: 417-420 (2004). *

• Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin. Gastroenterol. Hepatol. 2: 957-967 (2004).

• Krammer HJ, Schlieger F, Harder H, Franke A, Singer MV. Probiotics as therapeutic agents in irritable bowel syndrome. Z. Gastroenterol. 43: 467-471 (2005).

• Krausz MM, Duek SD. Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis and familial adenomatous polyposis: twenty years follow-up in 174 patients. Isr. Med. Assoc. J. 7: 23-27 (2005). *

• Kroesen AJ. Clinical appearance and therapy of pouchitis. Chir. Gastroenterol. 18: 356-363 (2002).

• Kroesen AJ, Dullat S, Schulzke JD, Fromm M, Buhr HJ. Permanently increased mucosal permeability in patients with backwash ileitis after ileoanal pouch for ulcerative colitis. Scand. J. Gastroenterol. 43: 704-711 (2008). *

• Kroesen AJ, Leistenschneider P, Lehmann K, Ransco C, Dullat S, Blaut M, Schulzke JD, Fromm M, Buhr HJ. Increased bacterial permeation in long-lasting ileoanal pouches. Inflamm. Bowel Dis. 12: 736-744 (2006). *

• Kruis W. Antibiotics and probiotics in inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 75-78 (2004). *

• Kuehbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Folsch UR, Kamm MA, Schreiber S. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55: 833-841 (2006). *

• Kuhbacher T, Gionchetti P, Hampe J, Helwig U, Rosenstiel P, Campieri M, Buhr HJ, Schreiber S. Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. Clin. Exp. Immunol. 123: 395-401 (2001). *

• Kuhbacher T, Schreiber S, Runkel N. Pouchitis: pathophysiology and treatment. Int. J. Colorectal Dis. 13: 196-207 (1998). *

• Kuisma J, Jarvinen H, Kahri A, Farkkila M. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand. J. Gastroenterol. 39: 544-548 (2004). *

• Kuisma J, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Risk of osteopenia after proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis. Scand. J. Gastroenterol. 37: 171-176 (2002). *

• Kuisma J, Mentula S, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Factors associated with ileal mucosal morphology and inflammation in patients with ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon Rectum 46: 1476-1483 (2003).

• Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am. J. Gastroenterol. 96: 3110-3116 (2001). *

• Laake KO, Line PD, Grzyb K, Aamodt G, Aabakken L, Roset A, Hvinden AB, Bakka A, Eide J, Bjorneklett A, Vatn MH. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand. J. Gastroenterol. 39: 1228-1235 (2004). *

• Lahat G, Halperin D, Barazovsky E, Shalit I, Rabau M, Klausner J, Fabian I. Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice. Inflamm. Bowel Dis. 13: 557-565 (2007). *

• Lammers K, Ouburg S, Morre SA, Crusius JB, Gionchett P, Rizzello F, Morselli C, Caramelli E, Conte R, Poggioli G, Campieri M, Pena AS. Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J. Gastroenterol. 11: 7323-7329 (2005). *

• Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm MA, Brigidi P, Gionchetti P, Campieri M. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am. J. Gastroenterol. 97: 1182-1186 (2002). *

• Lammers KM, Vergopoulos A, Babel N, Gionchetti P, Rizzello F, Morselli C, Caramelli E, Fiorentino M, D'errico A, Volk HD, Campieri M. Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Inflamm. Bowel Dis. 11: 447-454 (2005). *

• Lashner BA. Clinical advances in ulcerative colitis. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).

• Lavagna A, Bergallo M, Daperno M, Sostegni R, Ravarino N, Crocella L, Ramella A, Rocca R, Torchio B, Cavallo R, Pera A. The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis. Dig. Liver Dis. 38: 887-893 (2006).

• Leal RF, Ayrizono MD, Milanski M, Fagundes JJ, Moraes JC, Meirelles LR, Velloso LA, Coy CS. Detection of epithelial apoptosis in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. J. Transl. Med. 8: 11 (2010). *

• Leal RF, Coy CS, Ayrizono ML, Fagundes JJ, Milanski M, Saad MJ, Velloso LA, Goes JR. Differential expression of pro-inflammatory cytokines and a pro-apoptotic protein in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. Tech. Coloproctol. 12: 33-38 (2008). *

• Leenen CH, Dieleman LA. Inulin and oligofructose in chronic inflammatory bowel disease. J. Nutr. 137: 2572S-2575S (2007). *

• Leowardi C, Hinz U, Tariverdian M, Kienle P, Herfarth C, Ulrich A, Kadmon M. Long-term outcome 10 years or more after restorative proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. Langenbecks Arch. Surg. 395: 49-56 (2010).

• Lepisto A, Karkkainen P, Jarvinen HJ. Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm. Bowel Dis. 14: 775-779 (2008). *

• Lian L, Fazio VW, Lavery IC, Hammel J, Remzi FH, Shen B. Evaluation of association between precolectomy thrombocytosis and the occurrence of inflammatory pouch disorders. Dis. Colon Rectum 52: 1912-1918 (2009).

• Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J. Clin. Gastroenterol. 40: 669-677 (2006).

• Lichtman SN, Wang J, Hummel B, Lacey S, Sartor RB. A rat model of ileal pouch-rectal anastomosis. Inflamm. Bowel Dis. 4: 187-195 (1998). *

• Lillehei CW, Leichtner A, Bousvaros A, Shamberger RC. Restorative proctocolectomy and ileal pouch-anal anastomosis in children. Dis. Colon Rectum 52: 1645-1649 (2009).

• Linn FV, Peppercorn MA. Drug therapy for inflammatory bowel disease: part II. Am. J. Surg. 164: 178-185 (1992).

• Lisowska A, Banasiewicz T, Marciniak R, Drews M, Majewski P, Herzig KH, Walkowiak J. Chronic pouchitis is not related to small intestine bacterial overgrowth. Inflamm. Bowel Dis. 14: 1102-1104 (2008). *

• Lohsiriwat V, Clark SK. Persistent perineal sinus after ileoanal pouch excision in inflammatory bowel diseases: incidence, risk factors, and clinical course. Dis. Colon Rectum 51: 1795-1799 (2008). *

• Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm. Bowel Dis. 15: 454-462 (2009).

• Lovegrove RE, Tilney HS, Heriot AG, von Roon AC, Athanasiou T, Church J, Fazio VW, Tekkis PP. A comparison of adverse events and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. Dis. Colon Rectum 49: 1293-1306 (2006). *

• Lu H, Lian L, Navaneethan U, Shen B. Clinical utility of C-reactive protein in patients with ileal pouch anal anastomosis. Inflamm. Bowel Dis. Feb 23 [Epub ahead of print] (2010).

• Luukkonen P, Jarvinen H, Tanskanen M, Kahri A. Pouchitis - recurrence of the inflammatory bowel disease? Gut 35: 243-246 (1994). *

• M'koma AE. Serum biochemical evaluation of patients with functional pouches ten to 20 years after restorative proctocolectomy. Int. J. Colorectal Dis. 21: 711-720 (2006). *

• M'koma AE, Wise PE, Muldoon RL, Schwartz DA, Washington MK, Herline AJ. Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones. Int. J. Colorectal Dis. 22: 1143-1163 (2007). *

• Maamouri N, Belkahla N, Ouerghi H, Cheikh I, Ben Ammar A. Pouchitis treatment by probiotics. Tunis. Med. 83: 63-66 (2005).

• Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment. Pharmacol. Ther. 24: 701-714 (2006). *

• Mach T. Clinical usefulness of probiotics in inflammatory bowel diseases. J. Physiol. Pharmacol. 57 Suppl. 9: 23-33 (2007). *

• Macintyre A, Cymet TC. Probiotics: the benefits of bacterial cultures. Compr. Ther. 31: 181-185 (2005).

• Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591 (2001). *

• Madsen KL. The use of probiotics in gastrointestinal disease. Can. J. Gastroenterol. 15: 817-822 (2001). *

• Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 97: 910-914 (2002). *

• Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection - an unusual cause of refractory pouchitis: report of a case. Dis. Colon Rectum. 46: 267-270 (2003).

• Marciniak R, Majewski P, Banasiewicz T, Krokowicz P, Drews M, Janicka Jedynska M, Marciniak P. Diagnostic difficulties in pouchitis - experience from a single institution. Pol. J. Pathol. 55: 65-70 (2004).

• Marrero F, Qadeer MA, Lashner BA. Severe complications of inflammatory bowel disease. Med. Clin. North Am. 92: 671-686 (2008).

• Marteau P, Sokol H, Dray X, Seksik P. Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? Gastroenterol. Clin. Biol. 33S3: S228-S234 (2009).

• Maser EA, Present DH. Pouch-ouch. Curr. Opin. Gastroenterol. 24: 70-74 (2008). *

• Mathis KL, Dozois EJ, Larson DW, Cima RR, Sarmiento JM, Wolff BG, Heimbach JK, Pemberton JH. Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis. Br. J. Surg. 95: 882-886 (2008). *

• Matzke GM, Kang AS, Dozois EJ, Sandborn WJ. Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis. Colon Rectum 47: 782-786 (2004). *

• McGuire BB, Brannigan AE, O'Connell PR. Ileal pouch-anal anastomosis. Br. J. Surg. 94: 812-823 (2007). *

• McLaughlin SD, Clark SK, Bell AJ, Tekkis PP, Ciclitira PJ, Nicholls RJ. Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon Rectum 52: 879-883 (2009).

• McLaughlin SD, Clark SK, Tekkis PP, Ciclitira PJ, Nicholls RJ. Review article: restorative proctocolectomy, indications, management of complications and follow-up: a guide for gastroenterologists. Aliment. Pharmacol. Ther. 27: 895-909 (2008). *

• Meier CB, Hegazi RA, Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Duerr RH, Gorfine SR, Bauer JJ, Sachar DB, Plevy SE. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm. Bowel Dis. 11: 965-971 (2005). *

• Meier R, Lochs H. Pre- and probiotics. Ther. Umsch. 64: 161-169 (2007).

• Meier R, Steuerwald M. Place of probiotics. Curr. Opin. Crit. Care 11: 318-325 (2005).

• Metcalf AM. Elective and emergent operative management of ulcerative colitis. Surg. Clin. North Am. 87: 633-641 (2007).

• Michaels A, Levy C. Endoscopic and surgical management of primary sclerosing cholangitis. Medscape J. Med. 10: 242 (2008). *

• Millan M, Hull TL, Hammel J, Remzi F. Portal vein thrombi after restorative proctocolectomy: serious complication without long-term sequelae. Dis. Colon Rectum 50: 1540-1544 (2007). *

• Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53: 108-114 (2004). *

• Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment. Pharmacol. Ther. 19: 281-286 (2004). *

• Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment. Pharmacol. Ther. 23: 1403-1413 (2006). *

• Montalto M, Arancio F, Izzi D, Cuoco L, Curigliano V, Manna R, Gasbarrini G. Probiotics: history, definition, requirements and possible therapeutic applications. Ann. Ital. Med. Int. 17: 157-165 (2002).

• Moore L, Tang L, Lopez R, Shen B. Clinical features of ileal pouch-anal anastomosis in African American patients with underlying ulcerative colitis. Aliment. Pharmacol. Ther. 30: 385-391 (2009). *

• Morimoto K, Yamagami H, Hosomi S, Ohira M, Suekane T, Kamata N, Sogawa M, Watanabe K, Tominaga K, Watanabe T, Fujiwara Y, Tamori A, Oshitani N, Arakawa T. Development of pouchitis with combination therapy with Peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery. Am. J. Gastroenterol. 104: 1609-1610 (2009). *

• Morris JD, Diamond KA, Balart LA. Do probiotics have a role in the management of inflammatory bowel disease? J. La State Med. Soc. 161: 155-159 (2009).

• Murrell Z, Vasiliauskas E, Melmed G, Lo S, Targan S, Fleshner P. Preoperative wireless capsule endoscopy does not predict outcome after ileal pouch-anal anastomosis. Dis. Colon Rectum 53: 293-300 (2010).

• Murrell ZA, Melmed GY, Ippoliti A, Vasiliauskas EA, Dubinsky M, Targan SR, Fleshner PR. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis. Colon Rectum 52: 872-878 (2009).

• Nadgir RN, Soto JA, Dendrinos K, Lucey BC, Becker JM, Farraye FA. MRI of complicated pouchitis. AJR Am. J. Roentgenol. 187: W386-W391 (2006). *

• Naik VS, Patil SB, Scholefield J, Kaye PV, James PD, Ilyas M, Zaitoun AM. Adenocarcinoma arising in a background of chronic atrophic pouchitis in an ileoanal pouch for ulcerative colitis. Histopathology 53: 354-358 (2008). *

• Nakamura M, Ikeuchi H, Nakano H, Uchino M, Noda M, Yanagi H, Yamamura T. Postoperative joint symptoms: a risk factor for pouchitis in ulcerative colitis patients. Dig. Surg. 23: 60-64 (2006).

• Nasseri Y, Melmed G, Wang HL, Targan S, Fleshner P. Rigorous histopathological assessment of the colectomy specimen in patients with inflammatory bowel disease unclassified does not predict outcome after ileal pouch-anal anastomosis. Am. J. Gastroenterol. 105: 155-161 (2010). *

• Navaneethan U, Remzi FH, Nutter B, Fazio VW, Shen B. Risk factors for abnormal liver function tests in patients with ileal pouch-anal anastomosis for underlying inflammatory bowel disease. Am. J. Gastroenterol. 104: 2467-2475 (2009). *

• Navaneethan U, Shen B. Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors. Am. J. Gastroenterol. 105: 51-64 (2010). *

• Navaneethan U, Shen B. Laboratory tests for patients with ileal pouch-anal anastomosis: clinical utility in predicting, diagnosing, and monitoring pouch disorders. Am. J. Gastroenterol. 104: 2606-2615 (2009). *

• Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. Expert Rev. Gastroenterol. Hepatol. 3: 547-559 (2009).

• Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm. Bowel Dis. 13: 129-134 (2007). *

• Nicholls RJ. Review article: ulcerative colitis - surgical indications and treatment. Aliment. Pharmacol. Ther. 16 Suppl. 4: 25-28 (2002). *

• Nicholls RJ. Salvage surgery after restorative proctocolectomy. Acta Chir. Iugosl. 51: 23-26 (2004).

• Nilubol N, Scherl E, Bub DS, Gorfine SR, Marion J, Harris MT, Kornbluth A, Lichtiger S, Rubin P, George J, Chapman M, Harpaz N, Present D, Bauer JJ. Mucosal dysplasia in ileal pelvic pouches after restorative proctocolectomy. Dis. Colon Rectum 50: 825-831 (2007). *

• Norwood MG, Mann CD, West K, Miller AS, Hemingway D. Restorative proctocolectomy. Does ethnicity affect outcome? Colorectal Dis. 11: 972-975 (2009).

• O'Sullivan GC, Kelly P, O'halloran S, Collins C, Collins JK, Dunne C, Shanahan F. Probiotics: an emerging therapy. Curr. Pharm. Des. 11: 3-10 (2005).

• Ohge H, Furne JK, Springfield J, Rothenberger DA, Madoff RD, Levitt MD. Association between fecal hydrogen sulfide production and pouchitis. Dis. Colon Rectum 48: 469-475 (2005). *

• Okazaki K, Matsushita M, Kawamata S, Shimatani M, Fujii T. Diagnosis and medical treatment of pouchitis in ileal pouch-anal anastomosis in patients with ulcerative colitis. Nippon Rinsho 63: 885-889 (2005).

• Okon A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Ippoliti A, Targan SR, Fleshner PR. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am. Surg. 71: 821-826 (2005).

• Olveira Fuster G, Gonzalez-Molero I. Probiotics and prebiotics in clinical practice. Nutr. Hosp. 22 Suppl. 2: 26-34 (2007).

• Oresland T. Review article: colon-saving medical therapy vs. colectomy in ulcerative colitis - the case for colectomy. Aliment. Pharmacol. Ther. 24 Suppl. 3: 74-79 (2006). *

• Oresland T. Surgical treatment of refractory proctitis. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 80. May 7-8 (2004). *

• Page AV, Liles WC. Tumor necrosis factor-alpha inhibitor-induced lupus-like syndrome presenting as fever of unknown origin in a liver transplant recipient: case report and concise review of the literature. Transplant. Proc. 40: 1768-1770 (2008).

• Pakarinen MP, Koivusalo A, Natunen J, Ashorn M, Karikoski R, Aitola P, Rintala RJ, Kolho KL. Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric-onset ulcerative colitis. Inflamm. Bowel Dis. 16: 482-486 (2010).

• Pallone F, Del Vecchio Blanco G, Vavassori P, Monteleone I, Fina D, Monteleone G. Genetic and pathogenetic insights into inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 487-492 (2003).

• Pardi DS, D'Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm. Bowel Dis. 15: 1424-1431 (2009).

• Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. Aliment. Pharmacol. Ther. 23: 1087-1096 (2006). *

• Pardi DS, Shen B. Endoscopy in the management of patients after ileal pouch surgery for ulcerative colitis. Endoscopy 40: 529-533 (2008).

• Park IJ, Yu CS, Kim HC, Jung YH, Han KR, Yang SK, Kim JC. Analysis of pouchitis after restorative proctocolectomy. Korean J. Gastroenterol. 46: 99-104 (2005).

• Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, Lin D, Connor JT, Fazio VW, Lashner BA. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 126: 1280-1286 (2004). *

• Pastrana RJ, Torres EA, Arroyo JM, Rivera CE, Sanchez CJ, Morales L. Iron-deficiency anemia as presentation of pouchitis. J. Clin. Gastroenterol. 41: 41-44 (2007).

• Patel RT, Bain I, Youngs D, Keighley MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis. Colon Rectum 38: 831-837 (1995).

• Patel RT, Pall AA, Adu D, Keighley MR. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 7: 1037-1041 (1995).

• Patel RT, Stokes R, Birch D, Ibbotson J, Keighley MR. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Br. J. Surg. 81: 724-726 (1994).

• Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, Ilstrup D. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 38: 234-239 (1996). *

• Penner R, Fedorak RN, Madsen KL. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr. Opin. Pharmacol. 5: 596-603 (2005).

• Pereira SP, Rhodes JM, Campbell BJ, Kumar D, Bain IM, Murphy GM, Dowling RH. Biliary lactoferrin concentrations are increased in active inflammatory bowel disease: a factor in the pathogenesis of primary sclerosing cholangitis? Clin. Sci. (Lond.) 95: 637-644 (1998). *

• Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm. Bowel Dis. 12: 651-664 (2006). *

• Pham M, Lemberg DA, Day AS. Probiotics: sorting the evidence from the myths. Med. J. Aust. 188: 304-308 (2008). *

• Phillips MI. Antisense therapeutics: a promise waiting to be fulfilled. Methods Mol. Med. 106: 3-10 (2004).

• Philpott JR, Miner PB. Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD. Expert Opin. Biol. Ther. 8: 1627-1632 (2008).

• Piquet MA, Gloro R, Justum AM, Reimund JM. Nutritional therapy in inflammatory bowel disease. Gastroenterol. Clin. Biol. 30: 262-271 (2006).

• Pishori T, Dinnewitzer A, Zmora O, Oberwalder M, Hajjar L, Cotman K, Vernava AM 3rd, Efron J, Weiss EG, Nogueras JJ, Wexner SD. Outcome of patients with indeterminate colitis undergoing a double-stapled ileal pouch-anal anastomosis. Dis. Colon Rectum 47: 717-721 (2004). *

• Polese L, Angriman I, Giuseppe de F, Cecchetto A, Sturniolo GC, Renata D, Scarpa M, Ruffolo C, Norberto L, Frego M, D'Amico DF. Persistence of high CD40 and CD40L expression after restorative proctocolectomy for ulcerative colitis. World J. Gastroenterol. 11: 5303-5308 (2005). *

• Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis. 14: 662-668 (2008). *

• Quigley EM. Probiotics in the management of colonic disorders. Curr. Gastroenterol. Rep. 9: 434-440 (2007).

• Reumaux D, Colombel JF, Masy E, Duclos B, Heresbach D, Belaiche J, Cortot A, Duthilleul P; GETAID, Groupe d'Etude des Affections Inflammatoires du Tube Digestif. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm. Bowel Dis. 6: 270-274 (2000). *

• Rickard MJ, Young CJ, Bissett IP, Stitz R, Solomon MJ; Research Committee of the Colorectal Surgical Society of Australasia. Ileal pouch-anal anastomosis: the Australasian experience. Colorectal Dis. 9: 139-145 (2007). *

• Ringheanu M, Markowitz J. Inflammatory bowel disease in children. Curr. Treat. Options Gastroenterol. 5: 181-196 (2002).

• Rink AD, Radinski I, Vestweber KH. Does mesorectal preservation protect the ileoanal anastomosis after restorative proctocolectomy? J. Gastrointest. Surg. 13: 120-128 (2009). *

• Riobo P, Sanchez Vilar O, Burgos R, Sanz A. Colectomy management. Nutr. Hosp. 22 Suppl. 2: 135-144 (2007).

• Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 40: 260-263 (2006).

• Romero R. Postcolectomy ileitis. J. Clin. Gastroenterol. 38: S32 (2004).

• Rosenberg WM, Prince C, Kaklamanis L, Fox SB, Jackson DG, Simmons DL, Chapman RW, Trowell JM, Jewell DP, Bell JI. Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 345: 1205-1209 (1995).

• Roses RE, Rombeau JL. Recent trends in the surgical management of inflammatory bowel disease. World J. Gastroenterol. 14: 408-412 (2008). *

• Rowley S, Candinas D, Mayer AD, Buckels JA, McMaster P, Keighley MR. Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation. Gut 37: 845-847 (1995). *

• Rubin DT, Kornblunth A. Role of antibiotics in the management of inflammatory bowel disease: a review. Rev. Gastroenterol. Disord. 5 Suppl. 3: S10-S15 (2005).

• Rutgeerts P, Geboes K. Understanding inflammatory bowel disease - the clinician's perspective. Eur. J. Surg. Suppl. 586: 66-72 (2001).

• Sachar DB. How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis. 4: 165-166 (1998). *

• Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J. Gastroenterol. 14: 331-337 (2008). *

• Sako M, Kimura H, Arai K, Koganei K, Kito F, Sugita A, Fukushima T. Restorative proctocolectomy for pediatric patients with ulcerative colitis. Surg. Today 36: 162-165 (2006). *

• Sandborn W, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst. Rev. 2: CD001176 (2000). *

• Sandborn WJ. Inflammatory bowel disease: a new combination therapy for pouchitis. Rev. Gastroenterol. Disord. 5: 110 (2005). *

• Sandborn WJ, McLeod R, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm. Bowel Dis. 5: 33-39 (1999). *

• Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology 127: 1809-1814 (2004). *

• Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577-594 (2008). *

• Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr. Opin. Gastroenterol. 21: 44-50 (2005).

• Sartor RB. Microbial flora: mechanistic and therapeutic implications for IBD. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, p. 41 (2006). *

• Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633 (2004). *

• Sartor RB. Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr. Opin. Gastroenterol. 19: 358-365 (2003).

• Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr. Gastroenterol. Rep. 9: 497-507 (2007).

• Scarpa M, Angriman I, Ruffolo C, Ferronato A, Polese L, Barollo M, Martin A, Sturniolo GC, D'Amico DF. Health-related quality of life after restorative proctocolectomy for ulcerative colitis: long-term results. World J. Surg. 28: 124-129 (2004). *

• Scarpa M, Mescoli C, Rugge M, D'Inca R, Ruffolo C, Polese L, D'Amico DF, Sturniolo GC, Angriman I. Restorative proctocolectomy for inflammatory bowel disease: the Padova prognostic score for colitis in predicting long-term outcome and quality of life. Int. J. Colorectal Dis. 24: 1049-1057 (2009). *

• Schaus BJ, Fazio VW, Remzi FH, Bennett AE, Lashner BA, Shen B. Clinical features of ileal pouch polyps in patients with underlying ulcerative colitis. Dis. Colon Rectum 50: 832-838 (2007). *

• Schmidt C, Giese T, Ludwig B, Menges M, Schilling M, Meuer SC, Zeuzem S, Stallmach A. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int. J. Colorectal Dis. 21: 419-426 (2006). *

• Schmidt C, Hauser W, Giese T, Stallmach A. Irritable pouch syndrome is associated with depressiveness and can be differentiated from pouchitis by quantification of mucosal levels of proinflammatory gene transcripts. Inflamm. Bowel Dis. 13: 1502-1508 (2007). *

• Schmittenbecher P. Surgery for ulcerative colitis in pediatric patients: functional results of 10-year follow-up with straight endorectal pull-through. J. Pediatr. Surg. 40: 1216-1217 (2005).

• Schrumpf E, Jorgensen KK, Boberg KM. Primary sclerosing cholangitis, inflammatory bowel disease and treatment options. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 15-16 (2006). *

• Schultz M, Lindstrom AL. Rationale for probiotic treatment strategies in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 2: 337-355 (2008).

• Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 10: 585-590 (2008).

• Secondulfo M, Riegler G, De Magistris L, Belletta M, Fiandra R, Caserta L, Selvaggi F, Carratu R. Intestinal permeability assessment before and after ileal pouch-anal anastomosis. Minerva Gastroenterol. Dietol. 50: 155-163 (2004).

• Seetharamaiah R, West BT, Ignash SJ, Pakarinen MP, Koivusalo A, Rintala RJ, Liu DC, Spencer AU, Skipton K, Geiger JD, Hirschl RB, Coran AG, Teitelbaum DH. Outcomes in pediatric patients undergoing straight vs J pouch ileoanal anastomosis: a multicenter analysis. J. Pediatr. Surg. 44: 1410-1417 (2009).

• Seksik P, Dray X, Sokol H, Marteau P. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol. Nutr. Food Res. 52: 906-912 (2008). *

• Seksik P, Marteau P. Probiotics in inflammatory bowel disease: controlled trials and perspectives. Therapie 59: 83-87 2004.

• Semb S, Nordgaard-Lassen I. Treatment of fistulating pouchitis with tumour necrosis factor-alpha-inhibitor (infliximab). Ugeskr. Laeger. 170: 4134-4135 (2008).

• Sengul N, Wexner SD, Hui SM, Baig MK, Thomas N, Connor J, Weiss EG, Nogueras JJ, Berho M. Anatomic extent of colitis and disease severity are not predictors of pouchitis after restorative proctocolectomy for mucosal ulcerative colitis. Tech. Coloproctol. 10: 29-36 (2006).

• Setti Carraro PG, Talbot IC, Nicholls JR. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int. J. Colorectal Dis. 13: 103-107 (1998). *

• Setti-Carraro P, Talbot IC, Nicholls RJ. Longterm appraisal of the histological appearances of the ileal reservoir mucosa after restorative proctocolectomy for ulcerative colitis. Gut 35: 1721-1727 (1994). *

• Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm. Bowel Dis. 6: 107-115 (2000). *

• Shanahan F. Probiotics: promise, problems, and progress. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 41-45 (2006). *

• Shanahan F, Bernstein CN. Antibiotics as a first-line therapy for Crohn's disease: is there any consensus? Inflamm. Bowel Dis. 10: 324-326 (2004). *

• Shebani KO, Stucchi AF, Fruin B, McClung JP, Gee D, Beer ER, LaMorte WW, Becker JM. Pouchitis in a rat model of ileal J pouch-anal anastomosis. Inflamm. Bowel Dis. 8: 23-34 (2002). *

• Shen B. Diagnosis and treatment of patients with pouchitis. Drugs 63: 453-461 (2003).

• Shen B. Crohn's disease of the ileal pouch: reality, diagnosis, and management. Inflamm. Bowel Dis. 15: 284-294 (2009). *

• Shen B. Managing pouchitis. Am. J. Gastroenterol. 102 Suppl. 1: S60-S64 (2007). *

• Shen B, Achkar JP, Lashner BA, Ormsby AH, Brzezinski A, Soffer EE, Remzi FH, Bevins CL, Fazio VW. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am. J. Gastroenterol. 97: 972-977 (2002). *

• Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis. 7: 301-305 (2001). *

• Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment. Pharmacol. Ther. 22: 721-728 (2005). *

• Shen B, Fazio VW, Remzi FH, Bennett AE, Brzezinski A, Lopez R, Oikonomou I, Sherman KK, Lashner B. Risk factors for clinical phenotypes of Crohn's disease of the ileal pouch. Am. J. Gastroenterol. 101: 2760-2768 (2006). *

• Shen B, Fazio VW, Remzi FH, Bennett AE, Lavery IC, Lopez R, Brezinski A, Sherman KK, Bambrick ML, Lashner BA. Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch. Dis. Colon Rectum 50: 1450-1459 (2007). *

• Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, Brzezinski A, Oikonomou I, Sherman KK, Lashner BA. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis. Colon Rectum 50: 498-508 (2007). *

• Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, Lavery IC, Brzezinski A, Sherman KK, Lashner BA. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig. Dis. Sci. 52: 3321-3328 (2007). *

• Shen B, Fazio VW, Remzi FH, Brzezinski A, Bennett AE, Lopez R, Hammel JP, Achkar JP, Bevins CL, Lavery IC, Strong SA, Delaney CP, Liu W, Bambrick ML, Sherman KK, Lashner BA. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin. Gastroenterol. Hepatol. 4: 81-89 (2006). *

• Shen B, Fazio VW, Remzi FH, Delaney CP, Achkar JP, Bennett A, Khandwala F, Brzezinski A, Doumit J, Liu W, Lashner BA. Endoscopic balloon dilation of ileal pouch strictures. Am. J. Gastroenterol. 99: 2340-2437 (2004). *

• Shen B, Fazio VW, Remzi FH, Delaney CP, Bennett AE, Achkar JP, Brzezinski A, Khandwala F, Liu W, Bambrick ML, Bast J, Lashner B. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am. J. Gastroenterol. 100: 93-101 (2005). *

• Shen B, Fazio VW, Remzi FH, Lashner BA. Clinical approach to diseases of ileal pouch-anal anastomosis. Am. J. Gastroenterol. 100: 2796-2807 (2005). *

• Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig. Dis. Sci. 51: 2361-2364 (2006). *

• Shen B, Lashner B. Can we immunogenotypically and immunophenotypically profile patients who are at risk for pouchitis? Am. J. Gastroenterol. 99: 442-444 (2004). *

• Shen B, Lashner B. Diagnosis and treatment of ileal pouch diseases in patients with underlying ulcerative colitis. Curr. Treat. Options Gastroenterol. 9: 3-12 (2006).

• Shen B, Lashner BA. Pouchitis: a spectrum of diseases. Curr. Gastroenterol. Rep. 7: 404-411 (2005).

• Shen B, Lashner BA, Bennett AE, Remzi FH, Brzezinski A, Achkar JP, Bast J, Bambrick ML, Fazio VW. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am. J. Gastroenterol. 99: 1527-1531 (2004). *

• Shen B, Liu W, Remzi FH, Shao Z, Lu H, Delamotte C, Hammel J, Queener E, Bambrick ML, Fazio VW. Enterochromaffin cell hyperplasia in irritable pouch syndrome. Am. J. Gastroenterol. 103: 2293-2300 (2008). *

• Shen B, Pardi DS, Bennett AE, Queener E, Kammer P, Hammel JP, Laplaca C, Harris MS. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am. J. Gastroenterol. 104: 1468-1474 (2009). *

• Shen B, Patel S, Lian L. Natural history of Crohn's disease in patients who underwent intentional restorative proctocolectomy with ileal pouch-anal anastomosis. Aliment. Pharmacol. Ther. Dec 25 [Epub ahead of print] (2009). *

• Shen B, Plesec T, Remzi FH, Kariv R, Lopez R, Queener E, Fazio VW, Goldblum JR. Evaluation of tissue eosinophilia in the pouch and afferent limb in patients with restorative proctocolectomy. Inflamm. Bowel Dis. 14: 744-749 (2008). *

• Shen B, Plesec TP, Remer E, Kiran P, Remzi FH, Lopez R, Fazio VW, Goldblum JR. Asymmetric endoscopic inflammation of the ileal pouch: a sign of ischemic pouchitis? Inflamm. Bowel Dis. Dec 8 [Epub ahead of print] (2009).

• Shen B, Remzi FH, Brzezinski A, Lopez R, Bennett AE, Lavery IC, Queener E, Fazio VW. Risk factors for pouch failure in patients with different phenotypes Crohn's disease of the pouch. Inflamm. Bowel Dis. 14: 942-948 (2008). *

• Shen B, Remzi FH, Fazio VW. Fulminant Clostridium difficile-associated pouchitis with a fatal outcome. Nat. Rev. Gastroenterol. Hepatol. 6: 492-495 (2009).

• Shen B, Remzi FH, Hammel JP, Lashner BA, Bevins CL, Lavery IC, Wehkamp J, Fazio VW. Family history of Crohn's disease is associated with an increased risk for Crohn's disease of the pouch. Inflamm. Bowel Dis. 15: 163-170 (2009).

• Shen B, Remzi FH, Lavery IC, Lopez R, Queener E, Shen L, Goldblum J, Fazio VW. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment. Pharmacol. Ther. 29: 519-526 (2009). *

• Shen B, Remzi FH, Nutter B, Bennett AE, Lashner BA, Lavery IC, Brzezinski A, Bambrick ML, Queener E, Fazio VW. Association between immune-associated disorders and adverse outcomes of ileal pouch-anal anastomosis. Am. J. Gastroenterol. 104: 655-664 (2009).

• Shen B, Remzi FH, Oikonomou IK, Lu H, Lashner BA, Hammel JP, Skugor M, Bennett AE, Brzezinski A, Queener E, Fazio VW. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am. J. Gastroenterol. 104: 639-646 (2009).

• Shen B, Remzi FH, Santisi J, Lashner BA, Brzezinski A, Fazio VW. Application of wireless capsule endoscopy for the evaluation of iron deficiency anemia in patients with ileal pouches. J. Clin. Gastroenterol. 42: 897-902 (2008).

• Shen B, Wu H, Remzi F, Lopez R, Shen L, Fazio V. Diagnostic value of esophagogastroduodenoscopy in patients with ileal pouch-anal anastomosis. Inflamm. Bowel Dis. 15: 395-401 (2009).

• Shen BO, Jiang ZD, Fazio VW, Remzi FH, Rodriguez L, Bennett AE, Lopez R, Queener E, Dupont HL. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin. Gastroenterol. Hepatol. 6: 782-788 (2008).

• Shepherd NA, Healey CJ, Warren BF, Richman PI, Thomson WH, Wilkinson SP. Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir. Gut 34: 101-105 (1993). *

• Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, Campieri M, Morgenstern S, Rachmilewitz D. Variable response to probiotics in two models of experimental colitis in rats. Inflamm. Bowel Dis. 8: 399-406 (2002). *

• Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst. Rev. 1: CD004277 (2005).

• Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J. Surg. 24: 851-856 (2000). *

• Smith FM, Coffey JC, Kell MR, O'Sullivan M, Redmond HP, Kirwan WO. A characterization of anaerobic colonization and associated mucosal adaptations in the undiseased ileal pouch. Colorectal Dis. 7: 563-570 (2005). *

• Sokol H, Lay C, Seksik P, Tannock GW. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm. Bowel Dis. 14: 858-867 (2008). *

• Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 47: 415-422 (2000). *

• Stallmach A, Schmidt C. Ileo pouch-anal anastomosis. Internist (Berl.) 48: 606-611 (2007).

• Stein RB, Lichtenstein GR. Complications after ileal pouch-anal anastomosis. Semin. Gastrointest. Dis. 11: 2-9 (2000).

• Strong SA. Surgical treatment of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 441-446 (2002).

• Stucchi AF, Shebani KO, Reed KL, Gower AC, Alapatt MF, Crivello KM, McClung JP, Becker JM. Stasis predisposes ileal pouch inflammation in a rat model of ileal pouch-anal anastomosis. J. Surg. Res. May 3 [Epub ahead of print] (2009). *

• Sugita A, Koganei K, Kimura H, Yamada K, Futatuki R, Kitoh F, Fukushima T. Reconstruction of proctocolectomy: which is the best surgical procedure? Nippon Geka Gakkai Zasshi 109: 269-273 (2008).

• Takahashi K, Funayama Y, Fukushima K, Shibata C, Ogawa H, Sasaki I. Ileal J-pouch perforation at the blind end: report of a case. Surg. Today 39: 1080-1082 (2009). *

• Tang L, Cai H, Moore L, Shen B. Evaluation of endoscopic and imaging modalities in the diagnosis of structural disorders of the ileal pouch. Inflamm. Bowel Dis. Jan 4 [Epub ahead of print] (2010). *

• Tekkis PP, Heriot AG, Smith O, Smith JJ, Windsor AC, Nicholls RJ. Long-term outcomes of restorative proctocolectomy for Crohn's disease and indeterminate colitis. Colorectal Dis. 7: 218-223 (2005). *

• Tiainen J, Matikainen M. Long-term clinical outcome and anemia after restorative proctocolectomy for ulcerative colitis. Scand. J. Gastroenterol. 35: 1170-1173 (2000). *

• Toiyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg. Today 36: 287-290 (2006). *

• Toiyama Y, Araki T, Yoshiyama S, Miki C, Kusunoki M. Secondary pouchitis in a post-operative patient with ulcerative colitis, successfully treated by salvage surgery. World J. Gastroenterol. 11: 6888-6890 (2005). *

• Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 29: 2727-2737 (2009).

• Trovato C, Sonzogni A, Fiori G, Ravizza D, Tamayo D, Botti F, Carrara A, Zefelippo A, Contessini-Avesani E, Crosta C. Confocal laser endomicroscopy for the detection of mucosal changes in ileal pouch after restorative proctocolectomy. Dig. Liver Dis. 41: 578-585 (2009).

• Tulchinsky H, Dotan I, Alper A, Brazowski E, Klausner JM, Halpern Z, Rabau M. Comprehensive pouch clinic concept for follow-up of patients after ileal pouch anal anastomosis: report of 3 years' experience in a tertiary referral center. Inflamm. Bowel Dis. 14: 1125-1132 (2008). *

• Turina M, Pennington CJ, Kimberling J, Stromberg AJ, Petras RE, Galandiuk S. Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: effect on quality of life. J. Gastrointest. Surg. 10: 600-606 (2006).

• Tursi A. Balsalazide plus high-potency probiotic preparation (VSL#3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. J. Clin. Gastroenterol. 42 Suppl. 3: S119-S122 (2008).

• Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med. Sci. Monit. 10: PI126-PI131 (2004). *

• van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment. Pharmacol. Ther. 23: 1415-1425 (2006). *

• Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, Devos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm. Bowel Dis. 13: 135-142 (2007). *

• van Laarhoven CJ, Hueting WE, Schipper ME, Oostvogel HJ, Akkermans LM, van Vroonhoven TJ, Gooszen HG. Ileo-neorectal anastomosis: medium- and long-term follow-up of 37 patients. Dig. Surg. 21: 371-379 (2004).

• Vasiliauskas E. Recent advances in the diagnosis and classification of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 493-500 (2003).

• Vecchi M, Sinico A, Bianchi MB, Radice A, Gionchetti P, Campieri M, de Franchis R. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand. J. Gastroenterol. 33: 1284-1288 (1998). *

• Veerappan SG, Moinuddin G, Kennedy M, O'Morain CA, Kane D. Early diagnosis of bilateral sub-deltoid bursitis using clinic-based ultrasonography in a patient receiving infliximab therapy for ulcerative pouchitis. Ir. J. Med. Sci. Oct 24 [Epub ahead of print] (2008).

• Vento P, Kiviluoto T, Jarvinen HJ, Karkkainen P, Kivilaakso E, Soinila S. Expression of inducible and endothelial nitric oxide synthases in pouchitis. Inflamm. Bowel Dis. 7: 120-127 (2001). *

• Vento P, Lepisto A, Karkkainen P, Ristimaki A, Haglund C, Jarvinen HJ. Risk of cancer in patients with chronic pouchitis after restorative proctocolectomy for ulcerative colitis. Colorectal Dis. Oct 13 [Epub ahead of print] (2009). *

• Viscido A, Kohn A, Papi C, Caprilli R. Management of refractory fistulizing pouchitis with infliximab. Eur. Rev. Med. Pharmacol. Sci. 8: 239-246 (2004).

• Vucelic B. Therapy of inflammatory bowel disease. Med. Arh. 56: S37-S45 (2002).

• Walker WA, Goulet O, Morelli L, Antoine JM. Progress in the science of probiotics: from cellular microbiology and applied immunology to clinical nutrition. Eur. J. Nutr. 45 Suppl. 9: 1-18 (2006). *

• Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig KH. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand. J. Gastroenterol. 40: 1493-1494 (2005). *

• Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol. 1 Suppl. 1: S67-S74 (2008).

• Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima Jr H , Fellermann K, Ganz T, Stange EF, Bevins CL. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. U.S.A. 102: 18129-18134 (2005). *

• Wewer V, Hesselfeldt P, Qvist N, Husby S, Paerregaard A. J-pouch ileoanal anastomosis in children and adolescents with ulcerative colitis: functional outcome, satisfaction and impact on social life. J. Pediatr. Gastroenterol. Nutr. 40: 189-193 (2005). *

• Wu H, Shen B. Pouchitis and pouch dysfunction. Gastroenterol. Clin. North Am. 38: 651-668 (2009).

• Wu H, Shen B. Pouchitis: lessons for inflammatory bowel disease. Curr. Opin. Gastroenterol. 25: 314-322 (2009).

• Wu H, Shen B. Pouchitis and pouch dysfunction. Med. Clin. North Am. 94: 75-92 (2010).

• Yanaru-Fujisawa R, Matsumoto T, Nakamura S, Kochi S, Iida M, Kohda F, Hirahashi M, Yao T, Mibu R. Granulocyte apheresis for pouchitis with arthritis and pyoderma gangrenosum after restorative proctocolectomy for ulcerative colitis: a case report. Inflamm. Bowel Dis. 11: 780-781 (2005). *

• Yantiss RK, Farraye FA, O'Brien MJ, Fruin AB, Stucchi AF, Becker JM, Reddy SI, Odze RD. Prognostic significance of superficial fissuring ulceration in patients with severe "indeterminate" colitis. Am. J. Surg. Pathol. 30: 165-170 (2006).

• Yantiss RK, Sapp HL, Farraye FA, El-Zammar O, O'Brien MJ, Fruin AB, Stucchi AF, Brien TP, Becker JM, Odze RD. Histologic predictors of pouchitis in patients with chronic ulcerative colitis. Am. J. Surg. Pathol. 28: 999-1006 (2004).

• Yasuda N, Thomas P, Ellis H, Herbst F, Nicholls J, Ciclitira P. Perinuclear anti-neutrophil cytoplasmic antibodies in ulcerative colitis after restorative proctocolectomy do not correlate with the presence of pouchitis. Scand. J. Gastroenterol. 33: 509-513 (1998). *

• Yu ED, Shao Z, Shen B. Pouchitis. World J. Gastroenterol. 13: 5598-5604 (2007). *

• Zarate C A, Zuniga D A, Pinedo M G, Lopez K F, Molina P ME, Viviani G P. Ileal pouch-anal anastomosis for ulcerative colitis: complications and long term functional results. Rev. Med. Chil. 136: 467-474 (2008).

• Zins BJ, Sandborn WJ, Penna CR, Landers CJ, Targan SR, Tremaine WJ, Wiesner RH, Dozois RR. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am. J. Gastroenterol. 90: 2177-2181 (1995).

Number of references = 446

www psc-literature.org